Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Anistreplase APSAC for acute MI)
22 results
  • A review of the long term effects of thrombolytic agents. [Review]
    Drugs. 2000 Aug; 60(2):293-305.van Domburg RT, Boersma E, Simoons ML
  • Unequivocal evidence exists that reperfusion therapy, when given within 12 hours after onset of symptoms, saves the lives of patients with acute myocardial infarction (MI). As a result, the routine use of such treatment has increased rapidly since the mid-1980s but the rates of utilisation have been relatively static over the last decade at approximately 50% of patients with acute MI. The major q…
  • Supervision of thrombolysis of acute myocardial infarction using telemedicine. [Journal Article]
    J Telemed Telecare. 2000; 6(1):54-8.Mavrogeni SI, Tsirintani M, … Cokkinos DV
  • The treatment of acute myocardial infarction (MI) constitutes a significant problem in remote geographical areas of Greece. Furthermore, thrombolysis, the treatment of choice in the early phase of acute MI, requires the supervision of an expert. We have used thrombolytic treatment, using telemedicine, in remote medical centres. The Onassis Cardiac Surgery Centre was linked to six remote Aegean is…
  • [The effect of thrombolytic therapy with the preparation APSAC on the course of myocardial infarct]. [Clinical Trial]
    Ter Arkh. 1994; 66(9):41-5.Urazgil'deeva SA, Aminieva KhK, Varshavskiĭ SIu
  • To evaluate the influence of thrombolytic therapy (TT) on the course of acute myocardial infarction (AMI), a comparative analysis of clinical and pathological findings was conducted. The latter included post mortem examination of 35 myocardial samples from patients treated with APSAC in the acute phase of the infarction. The analysis indicated the predominance of cases with unfavourable coronary …
  • Thrombolysis: state of the art. [Review]
    Eur Heart J. 1993 Nov; 14 Suppl G:41-7.Sleight P
  • Thrombolytic treatment and aspirin will save about 50 in 1000 patients treated for acute myocardial infarction, but with a risk of cerebral or other serious bleeding in two to three in every 1000. Early treatment (< 4 h) about halves mortality; the benefits decline with time but are clearly proven up to 12 h from onset. Benefit is best and risk least when there is ST elevation and bundle branch (…
  • Intravenous thrombolytic therapy in myocardial infarction: an analytical review. [Review]
    Clin Cardiol. 1993 Apr; 16(4):283-92.Shammas NW, Zeitler R, Fitzpatrick P
  • The properties and physiological effects of three currently FDA-approved thrombolytic agents, streptokinase (SK), tissue plasminogen activator (tPA), and anisoylated plasminogen activator complex (APSAC) are reviewed. All thrombolytic agents have been shown to reduce mortality postmyocardial infarction (MI). Comparative trials have failed to demonstrate a difference between the effects of tPA, SK…
  • "Brain attack": an indication for thrombolysis? [Review]
    Ann Pharmacother. 1992 Jan; 26(1):73-80.Fagan SC, Zarowitz BJ, Robert S
  • CONCLUSIONS: Pharmacists need to be knowledgeable of new treatments of stroke and the risks associated with them. As patient educators, pharmacists can contribute to public awareness by promoting the early recognition of stroke symptoms. As pharmacotherapists, pharmacists need to understand the risks and the important monitoring parameters related to thrombolysis. The results of ongoing multicenter clinical trials are awaited before making a final judgment on the usefulness of thrombolysis in acute ischemic stroke.
  • Thrombolytic therapy in acute MI. Weighing the risks and benefits. [Review]
    Postgrad Med. 1990 Dec; 88(8):79-80, 83-6, 89-90 passim.Ro KG, Anderson HV
  • The underlying cause of acute myocardial infarction can now be effectively treated with thrombolytic agents, thereby increasing myocardial salvage and reducing mortality. Clinicians should always be aware of the risk-to-benefit ratio in treating patients with thrombolytic agents and treat each patient on an individual basis.
  • Thrombolytic therapy in acute myocardial infarction. [Review]
    Chest. 1990 Apr; 97(4 Suppl):136S-145S.Rutherford JD, Braunwald E
  • Recombinant tissue-type plasminogen activator (rt-PA), streptokinase (SK), and anisoylated plasminogen-streptokinase activator complex (APSAC) have salutary effects on mortality when administered to patients with evolving acute myocardial infarction (MI). Studies suggest that intravenous rt-PA is more effective in reperfusing occluded infarct-related arteries than SK, and the results of ongoing s…
  • Interventions in acute myocardial infarction. [Review]
    Circulation. 1990 Mar; 81(3 Suppl):IV43-50.Ellis SG
  • Results of multiple studies have amply verified the benefit of urgent coronary revascularization for patients who have acute myocardial infarction (MI). Currently, intravenous thrombolytic therapy is the treatment of choice for many patients, especially those 75 years old or younger who present within 6 hours of symptom onset and who are without contraindications to thrombolytic therapy. Some pat…
  • Reperfusion, patency and reocclusion with anistreplase (APSAC) in acute myocardial infarction. [Review]
    Am J Cardiol. 1989 Jul 05; 64(2):12A-17A; discussion 24A-26A.Anderson JL
  • Because the reestablishment of coronary blood flow is believed to be central to the benefit of thrombolytic therapy, measurements of reperfusion (i.e., angiography before and after therapy), patency (i.e., angiography after therapy) and reocclusion rates are important to the evaluation of new thrombolytic therapies. For anisoylated plasminogen streptokinase activator complex (APSAC, anistreplase)…
New Search